Characterizing the Network of Drugs and Their Affected Metabolic Subpathways

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Li, Chunquan ^a   Shang, Desi ^a   Wang, Yan ^a   Li, Jing ^a   Han, Junwei ^a   Wang, Shuyuan ^a   Yao, Qianlan ^a   Wang, Yingying ^a   Zhang, Yunpeng ^a   Zhang, Chunlong ^a   Xu, Yanjun ^a   Jiang, Wei ^a   Li, Xia ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DERMATOLOGICAL AGENT; DRUG; GASTROINTESTINAL AGENT; HEMATOLOGIC AGENT; IMMUNOMODULATING AGENT; RESPIRATORY TRACT AGENT; SEX HORMONE;

ADRENAL GLAND; ARTICLE; BONE MARROW; COMPUTER NETWORK; DATA BASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDICATION; DRUG METABOLIC SUBPATHWAY NETWORK; DRUG METABOLISM; GENE EXPRESSION; HUMAN; KIDNEY PARENCHYMA; LIVER PARENCHYMA; TISSUE SPECIFICITY; TRACHEA; UNSPECIFIED SIDE EFFECT;

ADRENAL GLANDS; BONE MARROW; GENE EXPRESSION REGULATION; HUMANS; KIDNEY; LIVER; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; TRACHEA;

EID: 84868104222     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047326     Document Type: Article

References (81)

1. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL, (2006) Global mapping of pharmacological space. Nat Biotechnol 24: 805-815.
2. Hu G, Agarwal P, (2009) Human disease-drug network based on genomic expression profiles. PLoS One 4: e6536.
3. Scheiber J, Chen B, Milik M, Sukuru SC, Bender A, et al. (2009) Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J Chem Inf Model 49: 308-317.
4. Hopkins AL, (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690.
5. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M, (2007) Drug-target network. Nat Biotechnol 25: 1119-1126.
6. Barabasi AL, Oltvai ZN, (2004) Network biology: understanding the cell's functional organization. Nat Rev Genet 5: 101-113.
7. Papin JA, Reed JL, Palsson BO, (2004) Hierarchical thinking in network biology: the unbiased modularization of biochemical networks. Trends Biochem Sci 29: 641-647.
8. Sridhar P, Song B, Kahveci T, Ranka S (2008) Mining metabolic networks for optimal drug targets. Pac Symp Biocomput: 291-302.
9. Kell DB, (2006) Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Discov Today 11: 1085-1092.
10. Tamada Y, Imoto S, Tashiro K, Kuhara S, Miyano S, (2005) Identifying drug active pathways from gene networks estimated by gene expression data. Genome Inform 16: 182-191.
11. Guimera R, Nunes Amaral LA, (2005) Functional cartography of complex metabolic networks. Nature 433: 895-900.
12. Hatzimanikatis V, Li C, Ionita JA, Broadbelt LJ, (2004) Metabolic networks: enzyme function and metabolite structure. Curr Opin Struct Biol 14: 300-306.
13. Barabasi AL, Gulbahce N, Loscalzo J, (2011) Network medicine: a network-based approach to human disease. Nat Rev Genet 12: 56-68.
14. Chen X, Xu J, Huang B, Li J, Wu X, et al. (2011) A sub-pathway-based approach for identifying drug response principal network. Bioinformatics 27: 649-654.
15. Burkard TR, Rix U, Breitwieser FP, Superti-Furga G, Colinge J, (2010) A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib. PLoS Comput Biol 6: e1001001.
16. Nacher JC, Schwartz JM, (2011) Modularity in protein complex and drug interactions reveals new polypharmacological properties. PLoS One 7: e30028.
17. Li C, Li X, Miao Y, Wang Q, Jiang W, et al. (2009) SubpathwayMiner: a software package for flexible identification of pathways. Nucleic Acids Res 37: e131.
18. Berger SI, Iyengar R, (2009) Network analyses in systems pharmacology. Bioinformatics 25: 2466-2472.
19. Braun P, Rietman E, Vidal M, (2008) Networking metabolites and diseases. Proc Natl Acad Sci U S A 105: 9849-9850.
20. Oti M, Brunner HG, (2007) The modular nature of genetic diseases. Clin Genet 71: 1-11.
21. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P, (2008) Drug target identification using side-effect similarity. Science 321: 263-266.
22. Krejsa CM, Horvath D, Rogalski SL, Penzotti JE, Mao B, et al. (2003) Predicting ADME properties and side effects: the BioPrint approach. Curr Opin Drug Discov Devel 6: 470-480.
23. Oprea TI, Nielsen SK, Ursu O, Yang JJ, Taboureau O, et al. (2011) Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer-Aided Drug Repurposing. Mol Inform 30: 100-111.
24. Takarabe M, Okuda S, Itoh M, Tokimatsu T, Goto S, et al. (2008) Network analysis of adverse drug interactions. Genome Inform 20: 252-259.
25. Nacher JC, Schwartz JM, (2008) A global view of drug-therapy interactions. BMC Pharmacol 8: 5.
26. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
27. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, et al. (2006) From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34: D354-357.
28. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36: D901-906.
29. Xu J, Li CX, Li YS, Lv JY, Ma Y, et al. (2010) MiRNA-miRNA synergistic network: construction via co-regulating functional modules and disease miRNA topological features. Nucleic Acids Res 39: 825-836.
30. Robien K, Boynton A, Ulrich CM, (2005) Pharmacogenetics of folate-related drug targets in cancer treatment. Pharmacogenomics 6: 673-689.
31. Ulrich CM, Robien K, Sparks R, (2002) Pharmacogenetics and folate metabolism - a promising direction. Pharmacogenomics 3: 299-313.
32. Yuthavong Y, Kamchonwongpaisan S, Leartsakulpanich U, Chitnumsub P, (2006) Folate metabolism as a source of molecular targets for antimalarials. Future Microbiol 1: 113-125.
33. Bermingham A, Derrick JP, (2002) The folic acid biosynthesis pathway in bacteria: evaluation of potential for antibacterial drug discovery. Bioessays 24: 637-648.
34. Sauer K, Cooke MP, (2010) Regulation of immune cell development through soluble inositol-1,3,4,5-tetrakisphosphate. Nat Rev Immunol 10: 257-271.
35. Sudheer Kumar M, Sridhar Reddy B, Kiran Babu S, Bhilegaonkar PM, Shirwaikar A, et al. (2004) Antiinflammatory and antiulcer activities of phytic acid in rats. Indian J Exp Biol 42: 179-185.
36. Agam G, Shamir A, Shaltiel G, Greenberg ML, (2002) Myo-inositol-1-phosphate (MIP) synthase: a possible new target for antibipolar drugs. Bipolar Disord 4Suppl 1: 15-20.
37. Wacker MJ, Kosloski LM, Gilbert WJ, Touchberry CD, Moore DS, et al. (2009) Inhibition of thromboxane A2-induced arrhythmias and intracellular calcium changes in cardiac myocytes by blockade of the inositol trisphosphate pathway. J Pharmacol Exp Ther 331: 917-924.
38. Dong Z, Huang C, Ma WY, (1999) PI-3 kinase in signal transduction, cell transformation, and as a target for chemoprevention of cancer. Anticancer Res 19: 3743-3747.
39. Antunes LC, Han J, Ferreira RB, Lolic P, Borchers CH, et al. (2011) The effect of antibiotic treatment on the intestinal metabolome. Antimicrob Agents Chemother.
40. Daum RS, (2007) Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 357: 380-390.
41. Rossi S (2006) Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook.
42. Ervens J, Schiffmann L, Berger G, Hoffmeister B, (2004) Colon perforation with acute peritonitis after taking clindamycin and diclofenac following wisdom tooth removal. J Craniomaxillofac Surg 32: 330-334.
43. Lehavi A, Sandler A, Netzer A, Shai Katz Y (2011) Vascular injury following accidental intra-arterial injection of clindamycin: adverse drug reaction report. Minerva Anestesiol.
44. Kim P, Younan N, Coroneo MT, (2002) Hypersensitivity reaction to intravitreal clindamycin therapy. Clin Experiment Ophthalmol 30: 147-148.
45. de Groot MC, van Puijenbroek EP, (2007) Clindamycin and taste disorders. Br J Clin Pharmacol 64: 542-545.
46. Lee SI, Lee JH, Lee SC, Lee JM, Lee JH, (2008) Calcium and neostigmine antagonize gentamicin, but augment clindamycin-induced tetanic fade in rat phrenic nerve-hemidiaphragm preparations. J Anesth 22: 385-390.
47. Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S, (2007) Clindamycin-induced acute cholestatic hepatitis. World J Gastroenterol 13: 5408-5410.
48. Kamaraj S, Anandakumar P, Jagan S, Ramakrishnan G, Devaki T, (2010) Modulatory effect of hesperidin on benzo(a)pyrene induced experimental lung carcinogenesis with reference to COX-2, MMP-2 and MMP-9. Eur J Pharmacol 649: 320-327.
49. Ren YP, Tang AG, Zhou QX, Xiang ZY, (2011) Clinical significance of simultaneous determination of serum tryptophan and tyrosine in patients with lung cancer. J Clin Lab Anal 25: 246-250.
50. Shigeta K, Ootaki K, Tatemoto H, Nakanishi T, Inada A, et al. (2002) Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by a Coptidis Rhizoma extract and protoberberine alkaloids. Biosci Biotechnol Biochem 66: 2491-2494.
51. Miller AL, (2005) Epidemiology, etiology, and natural treatment of seasonal affective disorder. Altern Med Rev 10: 5-13.
52. Russo S, Kema IP, Fokkema MR, Boon JC, Willemse PH, et al. (2003) Tryptophan as a link between psychopathology and somatic states. Psychosom Med 65: 665-671.
53. Extier A, Perruchot MH, Baudry C, Guesnet P, Lavialle M, et al. (2009) Differential effects of steroids on the synthesis of polyunsaturated fatty acids by human neuroblastoma cells. Neurochem Int 55: 295-301.
54. Guarner PT, El Hafidi M, Banos G (2011) Sex Hormones, Metabolic Syndrome and Kidney. Curr Top Med Chem.
55. Cuppoletti J, Tewari KP, Sherry AM, Malinowska DH, (2000) Activation of human CIC-2 Cl- channels: implications for cystic fibrosis. Clin Exp Pharmacol Physiol 27: 896-900.
56. Khan MM, Parikh VV, Mahadik SP, (2003) Antipsychotic drugs differentially modulate apolipoprotein D in rat brain. J Neurochem 86: 1089-1100.
57. Coersmeier C, Wittenberg HR, Aehringhaus U, Dreyling KW, Peskar BM, et al. (1986) Effect of anti-inflammatory and analgesic pyrazoles on arachidonic acid metabolism in isolated heart and gastric mucosa preparations. Agents Actions Suppl 19: 137-154.
58. Chen CT, Green JT, Orr SK, Bazinet RP, (2008) Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins Leukot Essent Fatty Acids 79: 85-91.
59. Sanchez-Mejia RO, Mucke L, (2010) Phospholipase A2 and arachidonic acid in Alzheimer's disease. Biochim Biophys Acta 1801: 784-790.
60. Hugues FC, Gourlot C, Le Jeunne C, (2000) [Drug-induced gynecomastia]. Ann Med Interne (Paris) 151: 10-17.
61. Fliri AF, Loging WT, Volkmann RA, (2007) Analysis of system structure-function relationships. ChemMedChem 2: 1774-1782.
62. Liebler DC, Guengerich FP, (2005) Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 4: 410-420.
63. Fliri AF, Loging WT, Thadeio PF, Volkmann RA, (2005) Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat Chem Biol 1: 389-397.
64. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P, (2010) A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 6: 343.
65. Li X, Li C, Shang D, Li J, Han J, et al. (2011) The Implications of Relationships between Human Diseases and Metabolic Subpathways. PLoS One 6: e21131.
66. Folkerd EJ, Dowsett M, (2010) Influence of sex hormones on cancer progression. J Clin Oncol 28: 4038-4044.
67. She X, Rohl CA, Castle JC, Kulkarni AV, Johnson JM, et al. (2009) Definition, conservation and epigenetics of housekeeping and tissue-enriched genes. BMC Genomics 10: 269.
68. Eisenberg E, Levanon EY, (2003) Human housekeeping genes are compact. Trends Genet 19: 362-365.
69. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, et al. (2007) The human disease network. Proc Natl Acad Sci U S A 104: 8685-8690.
70. Yao L, Rzhetsky A, (2008) Quantitative systems-level determinants of human genes targeted by successful drugs. Genome Res 18: 206-213.
71. Szabo S, Lippe IT, (1989) Adrenal gland: chemically induced structural and functional changes in the cortex. Toxicol Pathol 17: 317-329.
72. Swiader MJ, Luszczki JJ, Wielosz M, Czuczwar SJ, (2005) Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. Pharmacol Rep 57: 531-535.
73. Bengtsson U, Ahlstedt S, Aurell M, Kaijser B, (1975) Antazoline-induced immune hemolytic anemia, hemoglobinuria, and acute renal failure. Acta Med Scand 198: 223-227.
74. Tas C, Ozkan Y, Okyar A, Savaser A, (2007) In vitro and ex vivo permeation studies of etodolac from hydrophilic gels and effect of terpenes as enhancers. Drug Deliv 14: 453-459.
75. Inoue K, Hamada K, Ueda F, Shibata Y, Kimura K, (1994) Effect of anti-inflammatory agent etodolac on antigen-induced contractions of the trachea and lung parenchyma of guinea pigs. Prostaglandins Leukot Essent Fatty Acids 51: 451-455.
76. Hardisty JF, Brix AE, (2005) Comparative hepatic toxicity: prechronic/chronic liver toxicity in rodents. Toxicol Pathol 33: 35-40.
77. Qiao WJ, Cheng HY, Li CQ, Jin H, Yang SS, et al. (2011) Identification of pathways involved in paclitaxel activity in cervical cancer. Asian Pac J Cancer Prev 12: 99-102.
78. Li X, Jiang W, Li W, Lian B, Wang S, et al. (2012) Dissection of human MiRNA regulatory influence to subpathway. Brief Bioinform 13: 175-186.
79. Hopkins AL, (2009) Drug discovery: Predicting promiscuity. Nature 462: 167-168.
80. Lowe JA, Jones P, Wilson DM, (2010) Network biology as a new approach to drug discovery. Curr Opin Drug Discov Devel 13: 524-526.
81. Wang J, Zhang S, Wang Y, Chen L, Zhang XS, (2009) Disease-aging network reveals significant roles of aging genes in connecting genetic diseases. PLoS Comput Biol 5: e1000521.